ACHV - ACHIEVE LIFE SCIENCES, INC.
Region: US
Website: achievelifesciences.com
Employees: 20
IPO year: 1995
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company is based in Vancouver, Canada and has license agreements with Sopharma AD and University of Bristol.
Achieve Life Sciences announces publication of results from Phase 3 ORCA-3 trial
Achieve Life Sciences (ACHV) announced that complete trial results from its ORCA-3 were published in the Journal of the American Medical Association Internal Medicine. ORCA-3 was the second randomized, placebo-controlled Phase 3 clinical trial evaluating cytisinicline for smoking cessation in 792 U.S. adults. The authors concluded that ORCA-3 reaffirms cytisinicline’s efficacy and tolerability for smoking cessation in adult smokers at both 6- and 12-week treatment durations, including reduction
Read moreAchieve Life Sciences Expects to File New Drug Application in US for Smoking Cessation Medication
Achieve Life Sciences (ACHV) said it plans to file a new drug application with the US Food and Drug
Read moreAchieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline New Drug Application (NDA) Submission to FDA Planned for June 2025 SEATTLE and VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine depe
Read more